Figure 5.

HDAC6 inhibition or KD decreases the viability and promotes apoptosis in MDA-MB-231 and MDA-MB-468 differentiated breast cancer cells. (a and c) Tubastatin A-treated MDA-MB-231 and MDA-MB-468 cells were stained with MTS reagent and proliferation was determined 24 h post treatment. (b and d) MDA-MB-231 and MDA-MB-468 HDAC6 KD cells were stained with trypan blue and counted to determine the number of viable cells after 24, 48 and 72 h transfection. Tubastatin A-treated or HDAC6 KD MDA-MB-231 (e and f) or MDA-MB-468 (g and h) cells were subjected to WB analysis for CASP3. Tubastatin A-treated or HDAC6 KD MDA-MB-231 (i and j) or MDA-MB-468 (k and l) cells were stained with ANXA5-7-AAD and then analyzed by flow cytometry for the detection of apoptotic cells. Statistical analysis was performed with two-tailed, Student’s t-test with 95% confidence interval; *P-values = 0.05 obtained by comparing the respective data with the untreated or scrambled control.